| RELATED PARTY TRANSACTIONS |
21. RELATED PARTY TRANSACTIONS
As of December 31, 2025, amounts due from affiliates
consisted of the following:
| Name | | Amount | | | Relationship | | Note | | 3D Global | | $ | 33,636 | | | The Company’s CEO, the director of YD Biopharma, holds 12.85% of 3D Global shares | | Prepaid royalty fee | | EG BioMed | | $ | 291,540 | | | The Company’s CEO, the director of the Company, holds 45.3% of the shares of EG BioMed | | Prepayment of research and development expenses and other expenses |
As of December 31, 2024, the amount due from
an affiliate of the related parties in the above table was nil.
As of December 31, 2025, the amounts due to affiliates
consisted of the following:
| Name | | Amount | | | Relationship | | Note | | 3D Global | | $ | 350,400 | | | The Company’s CEO, the director of YD Biopharma, holds 12.85% of 3D Global shares | | Trade payables due to the Company, interest free and payment on demand. | | 3D Global | | $ | 420,429 | | | The Company’s CEO, the director of YD Biopharma, holds 12.85% of 3D Global shares | | Research and development expenses payable | | EG Bio USA | | $ | 48,471 | | | EG Bio USA is a wholly owned subsidiary of EG BioMed | | Service charge for laboratory payable |
As of December 31, 2024, the amounts due to affiliates
consisted of the following:
| Name | | Amount | | | Relationship | | Note | | EG BioMed | | $ | 37,086 | | | The Company’s CEO, the director of Company, holds 45.3% of the shares of EG BioMed | | Research and development expenses payable | | | | | | | | | | |
For the year ended December 31, 2025, the Company
had the following transactions with affiliates:
| Name | | Amount | | | Relationship | | Note | | 3D Global | | $ | 1,445,868 | | | The Company’s CEO, the director of Company, holds 12.85% of the shares of 3D Global | | Research and development expenses | | 3D Global | | $ | 1,880,523 | | | The Company’s CEO, the director of Company, holds 12.85% of the shares of 3D Global | | Sales of products to the Company | | 3D Global | | $ | 2,273 | | | The Company’s CEO, the director of Company, holds 12.85% of the shares of 3D Global | | Royalties | | EG BioMed | | $ | 17,003 | | | The Company’s CEO, the director of Company, holds 45.3% of the shares of EG BioMed | | Research and development expenses | | EG Bio USA | | $ | 138,471 | | | EG Bio USA is a wholly-owned subsidiary of EG BioMed | | Service charge for laboratory | | Ji Yan Biomedical Co., Ltd | | $ | 1,358 | | | The Company’s CEO, the director of Company, holds 75.94% of the shares of Ji Yan Biomedical Co., Ltd | | Sales by the Company | For the year ended December 31,2024, the Company
had the following transactions with affiliates:
| Name | | Amount | | | Relationship | | Note | | The Company’s CEO | | $ | 455,887 | | | Company director and major shareholder | | On August 31,2024, the Company issued 77,269 common shares with the par value of $0.10 each at $6.00 per shares to The Company’s CEO to Settle the amount due to The Company’s CEO. It represented the share capital of $7,727and the additional paid in capital of $455,887. | | EG BioMed | | $ | 1,848,000 | | | The Company’s CEO, the director of Company, holds 45.3% of the shares of EG BioMed | | Granting of EG BioMed Patent to the Company | | EG BioMed | | $ | 37,937 | | | The Company’s CEO, the director of Company, holds 45.3% of the shares of EG BioMed | | Research and development
expenses | | 3D Global | | $ | 952,381 | | | The Company’s CEO, the director of Company, holds 12.85% of the shares of 3D Global | | Granting of 3D Global Patent to the Company | | 3D Global | | $ | 453,416 | | | The Company’s CEO, the director of Company, holds 12.85% of the shares of 3D Global | | Research and development
expenses |
|